Targeted therapies have opened new perspectives in clinical oncology. However, clinicians have observed a lack of response in a relevant percentage of patients and frequent relapse in patients who initially respond. Therefore, a compelling challenge is to identify mechanisms underlying resistance and strategies to circumvent these hurdles. A growing body of evidence indicates that MET, the tyrosine kinase receptor for hepatocyte growth factor (HGF), is frequently implicated in resistance to targeted therapies. In this review, we highlight cell-autonomous and non-cell-autonomous mechanisms through which MET drives resistance, and we discuss some unsolved issues related to the selection of patients who could benefit from combined therapies. SIGNIFICANCE: Resistance is, at present, the major limitation to the efficacy of targeted therapies. Inappropriate MET activation is very frequently implicated in the onset of primary and secondary resistance to these therapies. Deciphering the role of the HGF/MET axis in resistance to different drugs could guide the design of new clinical trials based on combinatorial therapies, and it might help to overcome, or possibly prevent, the onset of resistance.

Cell-autonomous and non-cell-autonomous mechanisms of HGF/MET-driven resistance to targeted therapies: from basic research to a clinical perspective.

CORSO, Simona;GIORDANO, Silvia
2013-01-01

Abstract

Targeted therapies have opened new perspectives in clinical oncology. However, clinicians have observed a lack of response in a relevant percentage of patients and frequent relapse in patients who initially respond. Therefore, a compelling challenge is to identify mechanisms underlying resistance and strategies to circumvent these hurdles. A growing body of evidence indicates that MET, the tyrosine kinase receptor for hepatocyte growth factor (HGF), is frequently implicated in resistance to targeted therapies. In this review, we highlight cell-autonomous and non-cell-autonomous mechanisms through which MET drives resistance, and we discuss some unsolved issues related to the selection of patients who could benefit from combined therapies. SIGNIFICANCE: Resistance is, at present, the major limitation to the efficacy of targeted therapies. Inappropriate MET activation is very frequently implicated in the onset of primary and secondary resistance to these therapies. Deciphering the role of the HGF/MET axis in resistance to different drugs could guide the design of new clinical trials based on combinatorial therapies, and it might help to overcome, or possibly prevent, the onset of resistance.
2013
3
9
978
992
http://cancerdiscovery.aacrjournals.org/content/3/9/978.long
GROWTH-FACTOR RECEPTOR; PAPILLARY RENAL-CARCINOMAS; METASTATIC BREAST-CANCER; LUNG-CANCER; ACQUIRED-RESISTANCE; TYROSINE KINASE; MET PROTOONCOGENE; INVASIVE GROWTH; TRASTUZUMAB RESISTANCE; GEFITINIB RESISTANCE
Corso S;Giordano S
File in questo prodotto:
File Dimensione Formato  
CancerDiscovery_2014_APERTO.pdf

Open Access dal 01/08/2014

Tipo di file: POSTPRINT (VERSIONE FINALE DELL’AUTORE)
Dimensione 1.77 MB
Formato Adobe PDF
1.77 MB Adobe PDF Visualizza/Apri
2013_Cell-Autonomous and Non–Cell-Autonomous Mechanisms of HGFMET–Driven Resistance to Targeted Therapies.From Basic Research to a Clinical Perspective.pdf

Accesso riservato

Tipo di file: PDF EDITORIALE
Dimensione 1.82 MB
Formato Adobe PDF
1.82 MB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2318/142564
Citazioni
  • ???jsp.display-item.citation.pmc??? 43
  • Scopus 75
  • ???jsp.display-item.citation.isi??? 74
social impact